Results 171 to 180 of about 108,418 (353)
Basic biology and clinical application of specific cyclooxygenase-2 inhibitors [PDF]
Leslie J. Crofford+5 more
openalex +1 more source
L1CAM‐AS1 is identified as a novel H3K36me3‐guided, m6A‐modified long noncoding RNA (lncRNA) in hepatocellular carcinoma (HCC) cells. L1CAM‐AS1 stabilizes RAN protein, enhances M2 macrophages‐released CCL5‐induced nuclear import of RELA, activates the NF‐κB signaling, up‐regulates CCL2 expression and secretion from HCC cells, and enhances M2 ...
Teng Wang+6 more
wiley +1 more source
Cyclooxygenase-2–selective inhibitors impair glomerulogenesis and renal cortical development [PDF]
Martin Kömhoff+6 more
openalex +1 more source
The SNP rs2863002 at the 11p11.2 locus, identified through GWAS, is associated with an increased risk of neuroblastoma. The rs2863002‐C allele impairs the binding of the transcription factor GATA3, resulting in upregulation of the HSD17B12 gene.
Teresa Maiorino+20 more
wiley +1 more source
Preoperative oral treatment with cyclooxygenase‐2 inhibitor for cystitis glandularis
Introduction A previous report has shown that cyclooxygenase‐2 inhibitors can prevent the recurrence of cystitis glandularis postoperatively. Herein, we present a case of cystitis glandularis in which the tumor volume was markedly reduced by preoperative
Masato Yanagi+6 more
doaj +1 more source
INFLUENCE OF CYCLOOXYGENASE INHIBITORS ON PLASMA VOLUME AND PROTEIN DURING PROGRESSIVE EXERCISE
James M. Pivarnik+2 more
openalex +1 more source
Pischiutta F and coworkers identify prostaglandins and kynurenine as key mediators of the mesenchymal stromal cells‐derived secretome's neuroprotective effects. A synthetic cocktail composed of these factors promotes long‐term functional recovery, reduces brain structural damage, and modulates neuroinflammation after traumatic brain injury, supporting ...
Francesca Pischiutta+24 more
wiley +1 more source